Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended September 30, 2006 (Fiscal Year 2007)
Business Overview: Designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood, including single-use disposables and data management software.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2006 | 3 Months Ended Oct 1, 2005 | 6 Months Ended Sep 30, 2006 | 6 Months Ended Oct 1, 2005 |
|---|---|---|---|---|
| Net Revenues | $108,487 | $100,488 | $219,161 | $203,661 |
| Gross Profit | $55,162 | $51,765 | $112,535 | $106,289 |
| Gross Margin | 50.8% | 51.5% | 51.3% | 52.2% |
| Operating Income | $5,156 | $15,192 | $20,047 | $33,512 |
| Operating Margin | 4.8% | 15.1% | 9.1% | 16.5% |
| Net Income | $1,266 | $10,758 | $12,422 | $23,467 |
| Diluted EPS | $0.05 | $0.39 | $0.44 | $0.86 |
| Cash & Equivalents | $242,200 (as of Sep 30, 2006) | |||
| Working Capital | $325,690 (as of Sep 30, 2006) | |||
| Total Debt (Current + Long-term) | $34,612 (as of Sep 30, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 8.0% for the quarter and 7.6% year-to-date, driven primarily by growth in disposable sales (Plasma, Red Cell, and OrthoPAT lines) and software support. International revenues declined slightly due to foreign exchange headwinds.
- Profitability Decline: Operating income decreased 66.1% for the quarter and 40.2% year-to-date. Net income fell 88.2% for the quarter and 47.1% year-to-date.
- Acquisition Impact: The acquisition of Arryx, Inc. on July 18, 2006, resulted in a one-time $9.1 million in-process research and development (IPR&D) charge, significantly reducing operating income.
- Accounting Changes: Adoption of SFAS No. 123R (Share-based Payment) on April 2, 2006, introduced stock-based compensation expense of $5.3 million for the six-month period, which was not present in the prior year.
- Restructuring: The company recorded $2.7 million in restructuring costs related to the reorganization of international sales and service organizations.
- Tax Rate: The effective tax rate for the quarter was 82.2% (vs. 33.7% prior year) and 49.3% year-to-date (vs. 35.2% prior year), largely due to the non-deductible IPR&D charge.
Guidance, Outlook, and Risks
- Outlook: Management expects the annual tax rate to be approximately 35.5% for the remainder of fiscal year 2007. The company anticipates restructuring costs to total between $3 million and $4 million for the full fiscal year.
- Acquisition Integration: The Arryx acquisition adds holographic optical trapping (HOT) technology. The company estimates $11 million in total costs to complete the development of this platform by the end of fiscal year 2008.
- Foreign Exchange: Approximately 58% of sales are generated outside the U.S. (primarily Japan and Europe). A strengthening U.S. dollar negatively impacts reported results. The company uses forward contracts to hedge anticipated cash flows.
- Market Risks: Key risks include regulatory uncertainties, competitive pricing, industry consolidation (particularly in the plasma market), and the impact of communicable diseases on blood collection.
- Capital Allocation: The company has $25.7 million remaining on a $40.0 million share buyback program. Cash flow from operations remains strong, funding capital expenditures and acquisitions.
Investor Verification Checklist
- Acquisition Valuation: Verify the assumptions used in the $9.1 million IPR&D charge and the $14.9 million goodwill allocation for the Arryx acquisition.
- Stock Compensation Impact: Assess the long-term impact of SFAS 123R adoption on future operating margins, noting $21.4 million of unrecognized compensation cost remaining.
- Japan Market Exposure: Monitor the performance of the Japan Red Cross Society (JRC) customer, as plasma collections there decreased significantly compared to the prior year.
- Restructuring Execution: Track the realization of cost savings from the international sales and service reorganization against the projected $3–$4 million cost.
- Tax Rate Normalization: Confirm the return to the expected ~35.5% effective tax rate in subsequent quarters once discrete items (like the IPR&D charge) are excluded.